Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis

Haematologica

Volumn 96, Issue 4, 2011, Pages 552-557

  Soverini, Simona ^a   Vitale, Antonella ^b   Poerio, Angela ^a   Gnani, Alessandra ^a   Colarossi, Sabrina ^a   Iacobucci, Ilaria ^a   Cimino, Giuseppe ^b   Elia, Loredana ^b   Lonetti, Annalisa ^a   Vignetti, Marco ^b   Paolini, Stefania ^a   Meloni, Giovanna ^b   Maio, Valeria Di ^b   Papayannidis, Cristina ^a   Amabile, Marilina ^a   Guarini, Anna ^b   Baccarani, Michele ^a   Martinelli, Giovanni ^a   Foà, Robin ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Acute lymphoblastic leukemia; BCR ABL; Kinase domain mutations; Outcome

Indexed keywords

DASATINIB; IMATINIB;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; BCR ABL GENE; CANCER RESISTANCE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FOLLOW UP; GENE; GENETIC ASSOCIATION; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MALE; MISSENSE MUTATION; MOLECULAR CLONING; MUTATIONAL ANALYSIS; NONSENSE MUTATION; PHILADELPHIA 1 CHROMOSOME; POINT MUTATION; PROGNOSIS; RETROSPECTIVE STUDY; SEQUENCE ANALYSIS;

ADULT; AGED; AMINO ACID SUBSTITUTION; FEMALE; FUSION PROTEINS, BCR-ABL; GENE ORDER; HUMANS; MALE; MIDDLE AGED; MUTATION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RETROSPECTIVE STUDIES;

EID: 79953844396     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.034173     Document Type: Article

References (24)

1. Ottmann OG, Pfeifer H. First-line treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia in adults. Curr Opin Oncol. 2009;21(Suppl 1) S43-S46.
2. Soverini S, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A, et al. Contribution of ABL kinase domain mutations to ima-tinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res. 2006;12(24):7374-7379.
3. Hofmann WK, Komor M, Wassmann B, Jones LC, Gschaidmeier H, Hoelzer D, et al. Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lym-phoblastic leukemia.Blood. 2003;102(2):659-661.
4. Pfeifer H, Wassmann B, Pavlova A, Wunderle L, Oldenburg J, Binckebanck A, et al. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood. 2007;110(2):727-734.
5. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108(1):28-37.
6. Vignetti M, Fazi P, Cimino G, Martinelli G, Di Raimondo F, Ferrara F, et al. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol. Blood. 2007;109(9):3676-3678.
7. Soverini S, Martinelli G, Amabile M, Poerio A, Bianchini M, Rosti G, et al. Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib. Clin Chem. 2004;50(7):1205-1213.
8. Soverini S, Martinelli G, Rosti G, Bassi S, Amabile M, Poerio A, et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenet-ic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol. 2005;23(18):4100-4109.
9. Apperley JF. Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 2007;8(11):1018-1029.
10. Soverini S, Martinelli G, Colarossi S, Gnani A, Castagnetti F, Rosti G, et al. Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia. J Clin Oncol. 2006;24(33): e51-e52.
11. Soverini S, Colarossi S, Gnani A, Castagnetti F, Rosti G, Bosi C, et al. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the Bcr-Abl kinase domain. Haematologica. 2007;92(3):402-404.
12. Khorashad JS, Milojkovic D, Mehta P, Anand M, Ghorashian S, Reid AG, et al. In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib. Blood. 2008;111(4):2378-2381.
13. Jabbour E, Kantarjian HM, Jones D, Reddy N, O'Brien S, Garcia-Manero G, et al. Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood. 2008;112(13):4839-4842.
14. O'Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005;65(11):4500-4505.
15. Burgess MR, Skaggs BJ, Shah NP, Lee FY, Sawyers CL. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc Natl Acad Sci USA. 2005;102(9):3395-3400.
16. Redaelli S, Piazza R, Rostagno R, Magistroni V, Perini P, Marega M, et al. Activity of bosutinib, dasatinib, and nilo-tinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol. 2009;27 (3):469-471.
17. Faber E, Mojzikova R, Plachy R, Rozmanova S, Stastny M, Divoka M, et al. Major molecular response achieved with dasatinib in a CML patient with F317L BCR-ABL kinase domain mutation. Leuk Res. 2010;34(4):e91-e93.
18. Willis SG, Lange T, Demehri S, Otto S, Crossman L, Niederwieser D, et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenet-ic evolution but not response to therapy. Blood. 2005;106(6):2128-2137.
19. Kreuzer KA, Le Coutre P, Landt O, Na IK, Schwarz M, Schultheis K, et al. Preexistence and evolution of imatinib mesylate-resistant clones in chronic myel-ogenous leukemia detected by a PNA-based PCR clamping technique. Ann Hematol. 2003;82(5):284-289.
20. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, Lai JL, Philippe N, Facon T, et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood. 2002;100(3):1014-1018.
21. Kang HY, Hwang JY, Kim SH, Goh HG, Kim M, Kim DW. Comparison of allele specific oligonucleotide-polymerase chain reaction and direct sequencing for high throughput screening of ABL kinase domain mutations in chronic myeloid leukemia resistant to imatinib. Haematologica. 2006;91(5):659-662.
22. Ernst T, Gruber FX, Pelz-Ackermann O, Maier J, Pfirrmann M, Muller MC, et al. A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilo-tinib therapy after failure of imatinib. Haematologica. 2009;94(9):1227-1235.
23. Gruber FX, Ernst T, Kiselev Y, Hochhaus A, Mikkola I. Detection of drug-resistant clones in chronic myelogenous leukemia patients during dasatinib and nilotinib treatment. Clin Chem. 2010;56(3):469-473.
24. Preuner S, Denk D, Frommlet F, Nesslboeck M, Lion T. Quantitative monitoring of cell clones carrying point mutations in the BCR-ABL tyrosine kinase domain by liga-tion-dependent polymerase chain reaction (LD-PCR). Leukemia. 2008;22(10):1956-1961.